Sagimet Biosciences Debt to Equity

The latest debt-to-equity ratio for SGMT is 0.01. That is below the sector sector average of 0.2. Investors often review this figure alongside Sagimet Biosciences's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, SGMT currently prints 0.01 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 96.2% below the sector mean. Large gaps often invite a closer look at Sagimet Biosciences's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.01 for Sagimet Biosciences is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with SGMT's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting SGMT's debt-to-equity ratio (0.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.